Difference between revisions of "Team:Sheffield/episode9"
| Line 278: | Line 278: | ||
<p>Misusing antibiotics and producing a device, both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.</p> | <p>Misusing antibiotics and producing a device, both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.</p> | ||
| − | <p>Devices | + | <p>Devices containing GM live bacteria likely require reviews and approval from authorities, such as NICE (National Institute for Health and Care Excellence) and ISO, if they were used in real life applications. Design decisions should be made accordingly.</p> |
| − | <p>In addition to safety, managements of public and private providers should be consulted, for example, the NHS(National Health Service) and Bupa, to understand their demand. Business plans should be prepared when meeting with them. </p> | + | <p>In addition to safety, managements of public and private providers should be consulted, for example, the NHS(National Health Service) and Bupa, to understand their demand. This would allow forecasting how commonly the device would be used. Business plans should be prepared when meeting with them. </p> |
</div> | </div> | ||
Revision as of 08:59, 19 October 2016
|
THE FUTURE |
|
|---|
STUDYING INTRODUCTION TO THE MARKET
Here we discuss further work that future iGEM teams could carry out if they wish to expand on our work, more specifically on how the device would be introduced to the market.
Misusing antibiotics and producing a device, both require costs. The cost of a device in mass production should hence be modeled. If manufacturing in a large quantity would be more cost-saving than misusing antibiotics, it provides a case for investing. Data on the cost of materials should be collected to enable such calculation.
Devices containing GM live bacteria likely require reviews and approval from authorities, such as NICE (National Institute for Health and Care Excellence) and ISO, if they were used in real life applications. Design decisions should be made accordingly.
In addition to safety, managements of public and private providers should be consulted, for example, the NHS(National Health Service) and Bupa, to understand their demand. This would allow forecasting how commonly the device would be used. Business plans should be prepared when meeting with them.
